HOME >> BIOLOGY >> NEWS
Lancet study shows DiaPep277 arrests progression of Type 1 diabetes

Experimental drug DiaPep277 has been shown in a Phase II human clinical trial to arrest the progression of type 1 diabetes, prevent destruction of insulin-producing pancreatic cells, and reduce the need for injected insulin in newly diagnosed patients. Results of the study are published in the November 24, 2001 issue of The Lancet. The study was funded by Peptor, the biopharmaceutical company that is developing DiaPep277.

Our research has shown that it is possible to modulate the immune system and prevent or stop it from attacking the insulin-producing cells, said Dana Elias, Ph.D, Vice President, Research & Development, Peptor and lead investigator on the study. DiaPep277 holds the promise of becoming a breakthrough therapy for those already diagnosed with autoimmune diabetes, and perhaps a preventive treatment for those at high risk for the disease. If we reach patients early we may be able to improve the quality of their lives by significantly reducing their dependence on insulin. We may also halt or delay the development of complications and, possibly, extend patients lives.

Type 1 diabetes (formerly known as juvenile diabetes or insulin dependent diabetes mellitus) is a condition in which the immune system attacks and destroys insulin-producing beta cells in the pancreas.

This attack renders the pancreas unable to produce insulin, a hormone that controls blood sugar levels. People with type 1 diabetes must take insulin shots several times a day in order to survive. Late stage complications frequently include heart disease, stroke, high blood pressure, blindness, kidney disease, nervous system damage, amputations, dental disease, and pregnancy complications. People with this condition have a lifespan that is, on average, 15 years shorter than the norm.

Dr. Elias and colleagues at Peptor, along with research teams at Hadassah-Hebrew University Medical School and the Weizmann Institute of Science, conducted a ten-month ra
'"/>

Contact: Dennis Tartaglia
dennist@mbooth.com
212-481-7000
M Booth & Associates
22-Nov-2001


Page: 1 2 3 4

Related biology news :

1. Student science contest participation influences study, career choices, alumni say
2. New study shows hope for treating inhalant abuse
3. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
4. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
5. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
6. Phase II trials of second-generation antisense cancer drug planned following successful early study
7. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
8. Indiana University, EPA to study airborne PCBs
9. K-State, other universities to study how climate affects plant evolution
10. USC study links historical increases in life span to lower childhood exposure to infection
11. Washington University in St. Louis leads group studying aging process

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Lancet study shows DiaPep277 arrests progression Type diabetes

(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Endocrine Society (ENDO) 95th Annual Meeting in San ... are meant to promote the entry of students, ... mainstream of the basic science community and to ... ENDO 2013 Annual Meeting. , Awards are given ...
(Date:5/16/2013)... decades, scientists have used ancient shorelines to predict the stability ... of a high shoreline from three million years ago, for ... were thought to be evidence of a high sea ... assumption has led many scientists to think that if the ... may do just the same in our modern, progressively warming ...
(Date:5/16/2013)... The endothelium, the cellular layer lining the body,s ... few hundred nanometers in thickness, this super-tenuous structure ... tissue compression to create a unique and highly ... partition tissues from the body,s circulatory system. , ... barrier must be physically breached to enable ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
(Date:5/17/2013)... RURO Inc. is pleased to ... versatile refinement to the smart management solution. , ... advanced methodical management for transgenic animal colonies, genotyping ... network-based platform provides user access with a plethora ... to emphasize streamlined tasks, such as animal relocation ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 ... Barbara A. Myers, CAE, to the newly created ... her new role, Myers will be responsible for ... and production strategies, advancing the Society’s Member-led and ... and continuing to refine organizational, membership and product ...
(Date:5/16/2013)... Kitware , a leading provider ... Phase II SBIR funding from the U.S. Department ... open-source, high performance computing (HPC) simulation and computation ... to select only the toolkits and applications needed ... analysis tasks. , Manufacturers increasingly rely on ...
(Date:5/16/2013)... 2013 On average, developing a new ... billion dollars. Despite this investment, less than 10% of ... is your clinical trial design optimally structured to balance ... , Dr. Frederic Sax, Global Head of the Center ... of data, information and technology in upfront clinical trial ...
Breaking Biology Technology:RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2Kitware Develops a Customizable Simulation Framework to Provide HPC for Small to Mid-Sized Manufacturers 2Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2
Cached News: